Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flumazenil

FDA-approved product (injectable, injection), marketed as Flumazenil, Romazicon.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Flumazenil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Flumazenil. Its therapeutic class is shown instead.

WHO therapeutic group
Antidotes
FDA pharmacologic class
Benzodiazepine Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flumazenil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flumazenil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Reversal of Remimazolam by a Single Dose of Flumazenil

    NCT05382806 · start 2022-08-02

    Registered record
    Registry ID
    NCT05382806
    Conditions
    Flumazenil Adverse Reaction; Ambulatory Surgery; Postoperative Nausea; Remimazolam
    Interventions
    Flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-08-02
    Completion
    2023-05-13
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFlumazenil Adverse Reaction; Ambulatory Surgery; Postoperative Nausea; Remimazolam
    InterventionFlumazenil
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Remimazolam With Flumazenil vs. Propofol During RFCA for Atrial Fibrillation

    NCT05397886 · start 2022-08-02

    Registered record
    Registry ID
    NCT05397886
    Conditions
    Recovery
    Interventions
    Remimazolam Besylate; Flumazenil; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-08-02
    Completion
    2023-04-25
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecovery
    InterventionRemimazolam Besylate; Flumazenil; Propofol
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol

    NCT05435911 · start 2022-08-02

    Registered record
    Registry ID
    NCT05435911
    Conditions
    Recovery
    Interventions
    REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]; Flumazenil; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-08-02
    Completion
    2022-12-21
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecovery
    InterventionREMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]; Flumazenil; Propofol
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Recovery Profile After TIVA Between Remimazolam With Flumazenil and Propofol

    NCT05047939 · start 2021-12-14

    Registered record
    Registry ID
    NCT05047939
    Conditions
    Anesthesia, Intravenous
    Interventions
    remimazolam-based TIVA; propofol-based TIVA
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-12-14
    Completion
    2022-09-11
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnesthesia, Intravenous
    Interventionremimazolam-based TIVA; propofol-based TIVA
    PhaseNot applicable
    Registry statusCompleted

  • Sleep/Wake State Assessment with Non-invasive Earbuds

    NCT05066009 · start 2021-10-13

    Registered record
    Registry ID
    NCT05066009
    Conditions
    Hypersomnolence
    Interventions
    NextSense EEG-enabled earbuds; Ellcie Healthy eyeglasses; Drug Holiday
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-10-13
    Completion
    2023-10-27
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypersomnolence
    InterventionNextSense EEG-enabled earbuds; Ellcie Healthy eyeglasses; Drug Holiday
    PhaseNot applicable
    Registry statusCompleted

  • Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy

    NCT05468671 · start 2021-01-04

    Registered record
    Registry ID
    NCT05468671
    Conditions
    Endobronchial Metastases; Bronchoesophageal Fistula; General Anesthetic Drug Adverse Reaction
    Interventions
    Remimazolam; Propofol; Rocuronium; Remifentanil; oxycodone; Sugammadex Sodium; Flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-01-04
    Completion
    2022-09-08
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndobronchial Metastases; Bronchoesophageal Fistula; General Anesthetic Drug Adverse Reaction
    InterventionRemimazolam; Propofol; Rocuronium; Remifentanil +3 more
    PhasePhase 4
    Registry statusCompleted

  • GABA Antagonist to Improve Reversal of Anesthesia With High-density EEG Surveillance

    NCT04329585 · start 2020-03-25

    Registered record
    Registry ID
    NCT04329585
    Conditions
    Moderate Sedation; Colonoscopy
    Interventions
    flumazenil; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-03-25
    Completion
    2022-03-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate Sedation; Colonoscopy
    Interventionflumazenil; Placebos
    PhaseNot applicable
    Registry statusUnknown

  • PET with [18F]Flumazenil As an Index of Neurodegeneration in MS

    NCT03825601 · start 2019-05-02

    Registered record
    Registry ID
    NCT03825601
    Conditions
    Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis
    Interventions
    PET with [11C]Flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-05-02
    Completion
    2024-08-26
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Relapsing-Remitting Multiple Sclerosis
    InterventionPET with [11C]Flumazenil
    PhaseNot applicable
    Registry statusCompleted

  • Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination

    NCT03743805 · start 2019-01-01

    Registered record
    Registry ID
    NCT03743805
    Conditions
    Brain Death; Anoxic Brain Injury; Cardiac Arrest; Sedative Intoxication; Narcotic Intoxication
    Interventions
    Flumazenil; Naloxone
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2019-01-01
    Completion
    2021-07-21
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Death; Anoxic Brain Injury; Cardiac Arrest; Sedative Intoxication +1 more
    InterventionFlumazenil; Naloxone
    PhaseEarly phase 1
    Registry statusWithdrawn

  • Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm

    NCT03462641 · start 2018-03-09

    Registered record
    Registry ID
    NCT03462641
    Conditions
    Parkinson Disease
    Interventions
    Flumazenil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-03-09
    Completion
    2021-06-04
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionFlumazenil; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

    NCT03440112 · start 2018-01-29

    Registered record
    Registry ID
    NCT03440112
    Conditions
    Parkinson Disease
    Interventions
    Clarithromycin (Not used as of 4/2020); Placebo (Not used as of 4/2020); Transdermal flumazenil (Added 4/2020); Placebo (Added 4/2020)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-01-29
    Completion
    2021-12-08
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionClarithromycin (Not used as of 4/2020); Placebo (Not used as of 4/2020); Transdermal flumazenil (Added 4/2020); Placebo (Added 4/2020)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Neuroimaging GABA Physiology in Fragile X Syndrome

    NCT04308954 · start 2016-11-01

    Registered record
    Registry ID
    NCT04308954
    Conditions
    Fragile X Syndrome (FXS); Idiopathic Intellectual Developmental Disorder (IDD)
    Interventions
    [18F]flumazenil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2016-11-01
    Completion
    2018-12-06
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFragile X Syndrome (FXS); Idiopathic Intellectual Developmental Disorder (IDD)
    Intervention[18F]flumazenil
    PhasePhase 1
    Registry statusTerminated

  • A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy

    NCT03003884 · start 2016-11

    Registered record
    Registry ID
    NCT03003884
    Conditions
    Sedation
    Interventions
    Remimazolam Tosilate; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-11
    Completion
    2017-03
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSedation
    InterventionRemimazolam Tosilate; Propofol
    PhasePhase 2
    Registry statusCompleted

  • A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

    NCT02696512 · start 2016-03

    Registered record
    Registry ID
    NCT02696512
    Conditions
    Brain Injury
    Interventions
    Polypharmacy using FDA-approved products; Median Nerve Stimulation (MNS); Nutraceutical Supplementation; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2016-03
    Completion
    2017-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Injury
    InterventionPolypharmacy using FDA-approved products; Median Nerve Stimulation (MNS); Nutraceutical Supplementation; Standard of Care
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Electro-acupuncture and Flumazenil's Effect on Sedation

    NCT02690389 · start 2015-01

    Registered record
    Registry ID
    NCT02690389
    Conditions
    Acupuncture; General Anaesthesia; Sedation
    Interventions
    Flumazenil; Acupuncture
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-01
    Completion
    2015-08
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcupuncture; General Anaesthesia; Sedation
    InterventionFlumazenil; Acupuncture
    PhaseNot applicable
    Registry statusCompleted